Results 231 to 240 of about 91,755 (270)
Pembrolizumab vs Nivolumab as Initial Treatment for Advanced, Unresectable, or Metastatic Melanoma.
Strohbehn GW +3 more
europepmc +1 more source
Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal-Cell Carcinoma [PDF]
Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell ...
Nizar Tannir +2 more
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs of Today, 2014
Until recently, a treatment for advanced melanoma with a tolerable side effect profile has remained elusive. Therefore, despite its relatively rare occurrence, melanoma continues to cause the majority of skin cancer deaths, with less than 15% of those affected with late-stage disease surviving 10 years or more.
E, Fulchiero, A, Jimeno
openaire +2 more sources
Until recently, a treatment for advanced melanoma with a tolerable side effect profile has remained elusive. Therefore, despite its relatively rare occurrence, melanoma continues to cause the majority of skin cancer deaths, with less than 15% of those affected with late-stage disease surviving 10 years or more.
E, Fulchiero, A, Jimeno
openaire +2 more sources
Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma [PDF]
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial.
Lars Bastholt +2 more
exaly +2 more sources

